Aurinia Pharmaceuticals Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Aurinia Pharmaceuticals Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q2 2024.
  • Aurinia Pharmaceuticals Inc. Debt-to-equity for the quarter ending June 30, 2024 was 43.5 %, a 101% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 43.5 +21.9 +101% Jun 30, 2024
Q1 2024 42.5 +27.3 +179% Mar 31, 2024
Q4 2023 35.5 +21 +144% Dec 31, 2023
Q3 2023 28.3 +14.4 +104% Sep 30, 2023
Q2 2023 21.6 +6.85 +46.4% Jun 30, 2023
Q1 2023 15.2 -0.12 -0.78% Mar 31, 2023
Q4 2022 14.6 -0.79 -5.15% Dec 31, 2022
Q3 2022 13.9 -1.64 -10.6% Sep 30, 2022
Q2 2022 14.8 Jun 30, 2022
Q1 2022 15.3 Mar 31, 2022
Q4 2021 15.3 Dec 31, 2021
Q3 2021 15.5 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.